Ergo Science
Executive Summary
Work force reduced by 50% following receipt of "non-approvable" letter for the type 2 diabetes treatment Ergoset and the ensuing decision to discontinue funding of all pre-clinical development programs. Ergo Science Chairman, President and CEO Ronald Abrahams, PhD, will retire March 31